Background and Aims: The association between inflammatory bowel disease [IBD] and cancer remains poorly defined in Asian populations. Therefore, we conducted a nationwide populationbased study to determine the cancer risk in Korean patients with IBD. Methods: Using the National Health Insurance claims data, we collected data on patients diagnosed with IBD (5595 Crohn's disease [CD] and 10 049 ulcerative colitis [UC]) from 2011 to 2014. Standardized incidence ratios [SIRs] of overall and site-specific cancers in IBD patients in comparison with the general population were calculated. Results: The overall cancer risk was higher in CD patients [SIR, 2.2; 95% confidence interval, 1.5-3.0 in men and 3.3; 2.4-4.5 in women] and UC patients [1.9; 1.6-2.3 in men and 1.9; 1.5-2.4 in women]. There were significantly increased risks for the following cancers: small bowel cancer 
Introduction
Intestinal cancers are widely acknowledged as a long-term complication of inflammatory bowel diseases [IBDs] , probably because of chronic inflammation of the intestine. 1 A recent meta-analysis of Western population-based studies reported that the risk of colorectal cancer [CRC] among patients with IBD was 1.7 times higher than that in the general population, and it was lower than previously reported. 2 A decreasing trend over time may be attributed to changes in IBD management, such as the widespread use of immunosuppressive or biological agents, which may reduce the risk of CRC by suppressing intestinal inflammation. 3 On the other hand, given that extraintestinal manifestations are observed in up to 30% of patients with IBD, 4 IBD itself may increase the risk of extraintestinal cancers as well as intestinal cancers. Although population-based data regarding the risk of extraintestinal cancers are scare, the results of several studies suggest that patients with IBD are at increased risk of extraintestinal cancers, including lymphoma, [5] [6] [7] non-melanoma skin cancer [NMSC] [8] [9] [10] and melanoma. 8 The use of immunosuppressive agents may also contribute to the development of extraintestinal cancers. Some studies suggest that the use of thiopurines and biologics might be associated with an increased risk of lymphoma, 5-7 NMSC [8] [9] [10] or melanoma 8 Although the IBD incidence rate in Asian countries is still lower than the rates in Western countries, the incidence of IBD in Asia has been rapidly rising and the burden of IBD in this region has also been increasing. 11 The risk of cancer in IBD patients will also become a matter of concern in Asian countries. The epidemiology, phenotype and genetic susceptibility of Asian patients with IBD have been reported to differ from those of Western patients with IBD. 11, 12 For example, among Asian patients, there are more men with Crohn's disease [CD] , there is more ileocolonic involvement in CD and there are fewer extraintestinal manifestations; there are also differences in IBD susceptibility genes between Asian and Western patients. 11, 12 In addition, the types or incidences of cancers that occur in Western and Asian regions are slightly different. 13 Therefore, the risk of various cancers in patients with IBD may differ between Asian and Western patients. However, most population-based studies on cancer risk among patients with IBD have been conducted in Western countries. Although a few studies have examined the risk of cancer in Asian patients with IBD, most were not population-based studies in a hospital setting. [14] [15] [16] [17] [18] There are very limited population-based data on cancer risk among Asian patients with IBD. Therefore, we conducted a nationwide population-based study to determine the risk of intestinal cancer, extraintestinal cancer and overall cancer in the early stages of IBD in Korean patients.
Methods

Data source
As the Korean government operates a mandatory nationwide insurance system [National Health Insurance; NHI], all health care utilization information is registered under a comprehensive database operated by the Health Insurance and Review Agency [HIRA] . Using the HIRA database allows us to provide estimates based on the occurrence of events in unselected patient populations representing the whole spectrum of disease extent and severity.
This study used data from the NHI, which provides mandatory universal health insurance that covers all forms of health services including hospitalization, ambulatory care and pharmaceutical services. Medical institutions submit healthcare utilization information in electronic form for reimbursement purposes, and this information is integrated into the HIRA claims database, which covers the entire population of Korea [about 51 million]. The database contains information on all patients including demographic characteristics, ambulatory care history, principal diagnosis and comorbidity using International Classification of Disease 10th revision , prescriptions and procedures.
Patient identification
To increase the diagnostic accuracy of IBD, we enrolled only patients whose records showed a prescription for IBD medication as well as an appropriate diagnostic code. Specifically, the ICD-10 codes K51.0-51.9 denoted ulcerative colitis [UC], and codes K50.0-50.9 indicated CD. Regarding prescription, 5-aminosalicylic acid , immunomodulators [azathioprine or 6-mercaptopurine] or biologics [infliximab or adalimumab] were defined as IBD medications. More specifically, the prescriptions for IBD medication was defined in the following way: prescription of [1] 5-ASA for 1 month, [2] immunomodulators at least once and/or [3] biologics at least one time. A considerable number of IBD patients achieve remission without using corticosteroids in the early stages of the disease. In addition, the IBD treatment guidelines recommend that 5-ASA be used as the primary drug for the treatment of mild to moderate UC and CD. 19 Moreover, since corticosteroids cannot be used to maintain remission, they are rarely used alone for treating IBD. Supporting this, in several cohort studies, steroids were not used in approximately 25-60% of IBD patients during the first year after the initial diagnosis. 20 Moreover, a variety of doses of steroids can be administered due to other reasons, while 5-ASA, biologics and immunomodulators are rather specific to IBD treatment. For these reasons, we did not include the use of corticosteroids in the definition of IBD in our cohort.
The date of IBD registration in the HIRA database was regarded as the date of diagnosis. The source population for this study consisted of all NHI claims data from 2010 to 2014. Because previous prevalent cases may confound incidence, we used a washout period of 1 year. Thus, we could analyse patients with UC or CD diagnosed from January 1, 2011 to December 31, 2014.
Ascertainment of cancer
To calculate the standardized incidence rate [SIR] of cancer, it was necessary to determine the cancer incidence rate of the general population. Information regarding the source of cancer for patients with IBD was obtained from insurance claims [data from the NHI], and it was obtained from the National Cancer Registry [NCR] for the general population. The NCR is widely used as an official source of cancer data in Korea. A previous Korean study reported that the cancer incidence rates between the NCR and insurance claims data [data from the NHI] were comparable when the patients who had been admitted to the hospital because of cancer were considered incident cases. 21 In Korea, patients suspected of having cancer are usually hospitalized to enable a rapid diagnosis. The Korean government manages a registration programme for cancer in order to subsidize the medical expenses of patients with cancer. Through this programme, the Korean government covers 95% of the hospital expenses for patients with cancer, so that those patients pay for only 5% of their hospital expenses. Owing to these medical benefits, most Korean patients are hospitalized for further examinations and treatment at the time of first diagnosis of cancer. Based on these circumstances of the Korean medical system and the results of the previous Korean study, we contend that consideration of both the cancer code and hospitalization, as opposed to the cancer code alone, might improve the accuracy of the definition of cancer. Therefore, we considered hospital admission as well as the cancer code [ICD-10: C00-C96] when defining the occurrence of cancer. In other words, we defined cancer incident cases as those of patients admitted to the hospital for cancer. However, we also calculated the SIR of cancer when utilizing the cancer code data alone.
Statistical analysis
To determine whether patients with CD or UC had a higher risk of cancer incidence compared to the general population, we calculated the SIR [a ratio of observed to expected cancers] of overall and site-specific cancers in these patients. The number of observed cancer cases was the newly diagnosed cancer cases. The NCR provides information on the general population's incidence rate of cancer in 10-year intervals, from age 0 to 99. Using age-and sex-specific incidence rate data, the observed and expected numbers of cases were computed by different age-specific groups [10-year intervals] . The number of expected cancer cases was calculated by multiplying the age-specific cancer incidence rate of the general population from 2013 [as reported by the NCR and after standardization for sex and age] and the person-years of patients with UC or CD. The 95% confidence intervals [CIs] for the SIR were calculated using the Poisson distribution.
To investigate the association between medication and the risk of cancer incidence, a nested case control analysis was used, which would avoid the length bias produced by a regular case control analysis and would match exposure durations of cases and controls. We also matched the diagnosis dates of CD or UC to avoid temporal bias. For each subject who developed cancer during the follow-up period, four cancer-free subjects were randomly selected and matched to each cancer case with the same sex, age and diagnosis date of CD or UC. We then examined whether the cases and controls used medications during the period beginning with the diagnosis of CD or UC and ending with each case's respective cancer diagnosis date [for controls, their matching case's respective cancer diagnosis date]. Taking into account the matched case control data structure, we used conditional logistic regression to estimate the odds ratio [OR] and corresponding 95% CIs. SAS Enterprise Guide [SAS Institute, Inc.] was used for all statistical analyses. p values less than 0.05 were considered statistically significant.
Ethical considerations
All identifiable personal information in medical records had been de-identified to comply with the Health Insurance Portability and Accountability Act privacy rule. In addition, as the information in the HIRA database is encrypted, the database does not contain personal identifiers. This study protocol was approved by the Institutional Review Board of Severance Hospital, Yonsei University College of Medicine.
Results
Study population
In total, 5595 patients with CD and 10 049 patients with UC were newly diagnosed from 2011 to 2014. After excluding 89 patients with CD and 264 patients with UC with previous cancer, 5506 patients with CD and 9785 patients with UC were included in the present study and followed up until December 31, 2014 [ Figure 1 ].
The 5506 patients with CD were followed for 11 578 personyears [median follow-up time, 2.14 years; range, 0.003-3.99 years] and the 9785 patients with UC were followed for 21 048 personyears [median follow-up time, 2.20 years; range, 0.00-3.99 years]. Demographic and clinical characteristics of the study population are presented in Table 1 . The mean ages at diagnosis of patients with CD and UC were 31.9 ± 15.5 and 42.3 ± 16.3 years, respectively. The proportions of male patients with CD and UC were 71.2% and 59.5%, respectively.
Cancer risk in male patients with CD and UC
SIRs of site-specific cancer in male patients with CD and UC, compared with those of the general population, are presented in We further calculated the SIR of cancer when considering only the cancer code without considering hospitalization [Supplementary Table S1 ]. With the exception of a few types of cancer, the results were similar to those observed when both the cancer code and hospitalization were considered.
Cancer risk in female patients with CD and UC
SIRs of site-specific cancer in female patients with CD and UC, compared with the general population, are presented in Table 3 . Among the 1588 female patients with CD, 40 cancers were observed [vs 12.12 expected], which resulted in an increased overall cancer risk We further calculated the SIR of cancer when considering only the cancer codes, without consideration of hospitalization [Supplementary Table S2 ]. With the exception of a few cancers, the results were similar to those observed when both the cancer code and hospitalization were considered.
Risk of cancer according to medication use
In CD, the risk of small bowel cancer and CRC did not differ significantly between ever users and never users of 5-ASA or thiopurines. The risk of overall cancer was lower in ever users of 5-ASA than in never users of this drug [OR, 0.40; 95% CI, 0.19-0.81]. However, the use of thiopurines [OR, 0.82; 95% CI, 0.45-1.49] or biologics [OR, 1.41; 95% CI, 0.56-3.53] was not associated with the risk of overall cancer. Because all patients with haematologic cancer used 5-ASA, and no patients with small bowel cancer or CRC used biologics, we could not assess their association (Table 4) .
In UC, the risk of CRC and overall cancer did not differ significantly between ever users and never users of 5-ASA, thiopurines or biologics (Table 4) . 2,22 However, the SIRs of intestinal cancer for patients with IBD in our study were slightly higher than those observed in Western population-based studies. One of the reasons for this finding may be that the follow-up duration was shorter than those in Western population-based studies. The incidence of small bowel cancer is very low in the general population, and the shorter follow-up duration may result in bias. A hospital-based study from Korea also reported an increased SIR of CRC in patients with IBD (6.0 [95% CI, 3.1-10.5] for CD and 1.7 [95% CI, 1.0-2.7] for UC).
14 This study showed a higher SIR of CRC for patients with CD than our study, and this may be because hospital-based studies have a higher proportion of patients with more severe IBD.
In the present study, the risk of haematological cancer was higher in patients with CD and female patients with UC, but it was not higher in male patients with UC compared to the general population. The SIR of haematological cancer was elevated to 4.0 in male patients with CD, 11.0 in female patients with CD and 3.5 in female patients with UC. Regarding the subtype of haematological cancer, the risk of NHL was significantly higher in female patients with CD and UC, and the risk of leukaemia was significantly higher in female patients with CD. Several Western population-based studies showed similar results, finding that patients with IBD had a significantly higher risk of haematological cancer [SIR, 1.9-3.0]. 1, [23] [24] [25] A Korean hospital-based study also reported an increased risk of lymphoma in patients with CD [SIR, 4.3; 95% CI, 1.2-10.9]. 15 In addition to IBD, a variety of immune-mediated diseases have been reported to be associated with an increased risk of haematological cancer. 26, 27 Immune-mediated diseases and haematological cancers share common pathogenic mechanisms such as B-cell, T-cell and leukocyte activation and are characterized by similar genetic susceptibility or trigger factors [e.g. Epstein-Barr virus infection]. 27 These shared factors are thought to be mechanisms linking immune-mediated diseases and haematological cancers. The results of the present study demonstrate that the risk of haematological cancer was higher in the early stage of the disease, because we were able to investigate cancer risk only in the early stage of the disease [the median follow-up duration after IBD diagnosis was 2.1 years for CD and 2.2 years for UC]. The similar pathophysiological mechanisms of IBD and haematological cancers may lead to the early occurrence of haematological cancers in patients with IBD. In the current study, patients with IBD had an increased risk of certain extraintestinal solid cancers, as follows: cancer of the liver and pancreas in female patients with CD, cancer of the prostate, brain/ CNS and thyroid in male patients with UC, and cancer of the liver and cervix uteri in female patients with UC. The reported risks of extraintestinal solid cancer in patients with IBD vary across studies. A meta-analysis focusing on extraintestinal cancers in eight population-based IBD cohorts from Western countries demonstrated that patients with UC were at increased risk of liver-biliary cancer, but at decreased risk of pulmonary cancer, and that patients with CD were at increased risk of cancer of the upper gastrointestinal tract, lung, urinary tract and skin. 28 Similar to our results, a Danish populationbased study revealed that patients with UC had an increased risk of prostate cancer. 25 The study also reported an increased risk of cervical dysplasia [including carcinoma in situ] in patients with CD. 25 Although previous studies have shown inconsistent results regarding this topic, IBD itself seems to affect the development of some extraintestinal solid cancers as well as intestinal cancer. Considering that both our study and Western studies found that patients with IBD were at increased risk of cancer of the liver, cervix uteri and prostate, all patients with IBD should be aggressively vaccinated against hepatitis B and human papillomavirus at the time of diagnosis, regardless of race. Additionally, patients with IBD may have to undergo more thorough surveillance for prostate cancer [such as prostate-specific antigen and digital rectal examination] than what is being done currently. On the other hand, our results regarding skin cancer were different from those of Western studies. Western studies have reported an increased risk of skin cancer in patients with IBD, whereas in our study, Korean patients with IBD were not at increased risk of skin cancer [no patients with CD and only three patients with UC developed skin cancer]. Although regular dermatological screening and protection against ultraviolet radiation are recommended in Caucasians, 29 further studies are needed to ensure that such guidelines should apply equally to Asian patients with IBD. Because the risk of various malignancies in patients with IBD can differ among races, we believe that surveillance for malignancy may also be different according to race.
Several studies suggest that immunomodulators may reduce the risk of CRC by suppressing intestinal inflammation, 3, 30 whereas some studies suggest that immunomodulators may increase the risk of haematological cancers. 7, 24 In the present study, use of medications including 5-ASA, thiopurines or biologics was not associated with risk of intestinal cancer or haematologic cancer. Only use of 5-ASA was associated with lower overall cancer risk in patients with CD. However, the follow-up duration was too short to thoroughly evaluate the effect of medication use on risk of cancer. Future extended, long-term studies are needed to clarify the effects of medication use on cancer development.
Our study did not focus on cancer that occurred during treatment subsequent to a diagnosis of IBD, but rather on the relationship between IBD itself and cancer development. We speculate that patients with a predisposition toward developing IBD have dysregulated immune responses, which ultimately cause chronic inflammation that may precede the diagnosis of IBD, and that this dysregulated immune response may affect cancer development even in the early stages of the disease. Therefore, we did not exclude incident cancers diagnosed within the first year of IBD diagnosis. Moreover, given that a long diagnostic delay [long duration between symptom onset and IBD diagnosis] occurs in a considerable number of IBD patients [a recent study reported a mean diagnostic delay interval of 16.0 months 31 ], incident cancers diagnosed within the first year of IBD diagnosis must be investigated.
To date, few population-based studies have been conducted to determine the cancer risk among Asian patients with IBD. Only one recent study investigated the cancer risk of patients with IBD at the population level in Taiwan. 32 Similar to our results, the Taiwan study reported that patients with IBD had a higher risk of haematological cancers, but in contrast to our results, the study showed that the risk of CRC was not increased in patients either with CD or with UC. 32 We think that the cancer risk in patients with IBD will vary from country to country, even in the same Asian region, because each country has different ethnic and environmental backgrounds.
This second nationwide population-based study in Asia provides useful information about cancer risk in Asian patients with IBD. Nonetheless, this study has several limitations. First, we did not verify the diagnostic accuracy of IBD. As we used insurance claims data, it is possible that real patients with IBD might be missed or non-IBD patients might be misdiagnosed as having IBD. However, we consider our definition of IBD diagnosis to be quite reliable. The Korean government manages a registration programme for Rare Intractable Diseases [RID], including IBD, in order to subsidize the medical expenses of patients with rare intractable diseases. Through the RID programme, the Korean government covers 90% of the hospital expenses for patients with IBD, so that those patients pay for only 10% of their hospital expenses. A diagnosis of IBD is not likely to be missed in order to ensure access to these medical benefits. Conversely, confirmation of an IBD diagnosis is made according to very strict criteria. In addition, because IBD remains a rare disease in Korea, patients with IBD are generally diagnosed and managed at tertiary hospitals. 33 In other words, most patients with IBD in Korea were referred by primary care physicians and subsequently diagnosed and treated by IBD specialists at a tertiary hospital according to rigorous guidelines. Given these circumstances of the Korean medical system, we believe that the Korean diagnostic code defines IBD more accurately than do the diagnostic codes used in other countries. Moreover, to further increase the diagnostic accuracy of IBD, we considered prescriptions of immunomodulators and/or biologics, as well as 5-ASA, when defining IBD. Second, since we used administrative data, we could not obtain information on disease phenotype, such as location and behaviour of CD and disease extent of UC. Thus, we could not evaluate the cancer risk according to disease phenotype. In addition, we were unable to identify the time from disease onset to disease diagnosis because data pertaining to symptom onset were not available. However, given that the Korean government subsidizes the medical expenses of patients with IBD, a diagnosis of IBD is not likely to be delayed. Third, the duration of follow-up was too short to assess the development of IBD-associated cancers, completely. We could investigate cancer risk in the early stage of the disease, but not the long-term cancer risk. Nevertheless, our study showed that patients with IBD had an increased risk of intestinal cancer, haematological cancer and overall cancer in the early stage of the disease. We speculate that patients with a predisposition toward developing IBD have dysregulated immune responses even before the diagnosis of IBD, and this results in a high risk of cancer [especially intestinal cancer] even in the early stage of the disease. Fourth, there might have been a detection bias. Patients with IBD are more likely to seek health care and to need multiple physician visits, as compared to the general population, and thus they may have a higher rate of cancer detection than the general population. Finally, there was a limitation in evaluating the influence of medication use on cancer development because of the short follow-up period.
In conclusion, this Korean population-based study showed that patients with CD and UC were at an increased overall risk of cancer.
Patients with CD had an increased risk of small bowel cancer, CRC and haematologic cancer. Patients with UC also had an increased risk of CRC, and female patients with UC had an increased risk of haematological cancer. Moreover, Korean patients with IBD were at increased risk of some extraintestinal solid cancers. Further detailed and long-term studies are required to determine the cancer risk according to disease phenotype and treatment in Korean patients with IBD.
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